Trials / Completed
CompletedNCT02526017
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 313 (actual)
- Sponsor
- Five Prime Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.
Detailed description
This is a phase 1a/b single-arm, open-label study to evaluate safety, tolerability, pharmacokinetics (PK), and clinical benefit of cabiralizumab in combination with nivolumab in patients with selected advanced cancers.
Conditions
- Advanced Solid Tumors
- Head and Neck Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Malignant Glioma
- Non-small Cell Lung Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cabiralizumab | Solution for IV administration |
| BIOLOGICAL | Nivolumab | Solution for IV administration |
Timeline
- Start date
- 2015-09-08
- Primary completion
- 2019-11-18
- Completion
- 2019-11-18
- First posted
- 2015-08-18
- Last updated
- 2022-03-09
- Results posted
- 2022-03-09
Locations
39 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02526017. Inclusion in this directory is not an endorsement.